CN113509491A - 一种用于烫伤烧伤的组合物及其制备方法与用途 - Google Patents
一种用于烫伤烧伤的组合物及其制备方法与用途 Download PDFInfo
- Publication number
- CN113509491A CN113509491A CN202110490565.2A CN202110490565A CN113509491A CN 113509491 A CN113509491 A CN 113509491A CN 202110490565 A CN202110490565 A CN 202110490565A CN 113509491 A CN113509491 A CN 113509491A
- Authority
- CN
- China
- Prior art keywords
- burns
- composition
- weight
- scalds
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 239000008107 starch Substances 0.000 claims abstract description 26
- 235000019698 starch Nutrition 0.000 claims abstract description 26
- 239000002674 ointment Substances 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 229940099259 vaseline Drugs 0.000 claims abstract description 14
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 13
- 229920001353 Dextrin Polymers 0.000 claims abstract description 13
- 239000004375 Dextrin Substances 0.000 claims abstract description 13
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000006 Nitroglycerin Substances 0.000 claims abstract description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 13
- 235000019425 dextrin Nutrition 0.000 claims abstract description 13
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 239000011734 sodium Substances 0.000 claims abstract description 13
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 13
- 229960004793 sucrose Drugs 0.000 claims abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000005720 sucrose Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 claims abstract description 8
- 238000000227 grinding Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- 235000019439 ethyl acetate Nutrition 0.000 claims abstract description 4
- 235000015424 sodium Nutrition 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000001804 debridement Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 15
- 206010052428 Wound Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 238000005469 granulation Methods 0.000 abstract description 4
- 230000003179 granulation Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于烫伤烧伤的组合物及其制备方法与用途,该组合物包含以下成分:马来酸氯苯那敏,糊精、淀粉、磷酸氢钙、羧甲基淀粉钠、硬脂酸镁、醋酸酯、蔗糖、硝酸甘油、凡士林。本发明还提供了该用于烫伤烧伤的组合物的制备方法,该方法为:首先准备材料,然后将固体原料研磨成粉,再按比例与其他原料均匀混合,配制成膏状。本发明也提供了该方法制备的用于烫伤烧伤的组合物的用途,该组合物用于制备针对烧烫伤的的外敷药膏。本发明提供的用于烫伤烧伤的组合物,外用没有副作用,制备而成的药膏具有快速消炎、杀菌,以及清热解毒、止痛、生肌等作用,对创伤有明显效果,可以用于各种烧、烫、灼伤。
Description
技术领域
本发明涉及一种药物组合物及其制备方法与用途,具体地,涉及一种用于烫伤烧伤的组合物及其制备方法与用途。
背景技术
烧伤、烫伤是日常生活中经常会发生的一种意外的事故性的多发急性损伤,它们通常是人体受到外界不同因素伤害而引起的组织破坏。中医称“火烧疮”、“烫火伤”,其成因主要是由于火焰、热水等高温因素导致人体皮肤及皮下组织受到灼伤,使得皮毛不存,渗液流津,渍蚀肌肤。轻则影响美观,重则引起多种全身症状。如果不进行紧急处理或治疗,往往会造成患者受到极大的痛苦、留疤,甚至是引发感染造成并发症和后遗症。
目前,治疗烧烫伤的惯常方法主要是用外用药物涂抹或者敷贴于创面,并将伤口包裹起来防止感染。现有的外伤药膏对治疗烧烫伤等存在如下缺点:伤口愈合慢,治疗时间长,治疗期间有疼痛感,对于大面烧烫伤治疗效果差,治疗不当会留下疤痕等。
发明内容
本发明的目的是提供一种用于皮肤烧烫创伤的组合物及其制备方法与用途,该组合物能够快速止痛,达到修复表皮组织、防腐生肌、愈后不留疤痕等效果,外用没有副作用,而且药物配方简单,经济实惠。
为了达到上述目的,本发明提供了一种用于烫伤烧伤的组合物,其中,该组合物包含以下成分:马来酸氯苯那敏,糊精、淀粉、磷酸氢钙、羧甲基淀粉钠、硬脂酸镁、醋酸酯、蔗糖、硝酸甘油、凡士林。
上述的用于烫伤烧伤的组合物,其中,所述的组合物按重量份数计包含马来酸氯苯那敏0.3~0.6份,糊精0.3~0.6份、淀粉0.3~0.6份、磷酸氢钙0.3~0.6份、羧甲基淀粉钠0.3~0.6份、硬脂酸镁0.3~0.6份、醋酸酯0.3~0.6份、硝酸甘油0.3~0.6份、蔗糖4500~5500份、凡士林8000~12000份。
上述的用于烫伤烧伤的组合物,其中,所述的组合物按重量份数计包含马来酸氯苯那敏0.5份,糊精0.5份、淀粉0.5份、磷酸氢钙0.5份、羧甲基淀粉钠0.5份、硬脂酸镁0.5份、醋酸酯0.5份、硝酸甘油0.5份、蔗糖5000份、凡士林10000份。
上述的用于烫伤烧伤的组合物,其中,所述的组合物按重量计包含马来酸氯苯那敏0.5mg,糊精0.5mg、淀粉0.5mg、磷酸氢钙0.5mg、羧甲基淀粉钠0.5mg、硬脂酸镁0.5mg、醋酸酯0.5mg、硝酸甘油0.5mg、蔗糖5g、凡士林10g。
本发明还提供了上述的用于烫伤烧伤的组合物的制备方法,其中,所述的方法为:首先准备材料,然后将固体原料研磨成粉,再按比例与其他原料均匀混合,配制成膏状。
上述的用于烫伤烧伤的组合物的制备方法,其中,所述的方法中研磨成粉的粒度范围为50~80目。
本发明也提供了上述的方法制备的用于烫伤烧伤的组合物的用途,其中,所述的组合物用于制备针对烧烫伤的的外敷药膏。
上述的用于烫伤烧伤的组合物的用途,其中,所述的药膏在使用时,先将创面以无菌生理盐水清洁,在清创后将药膏敷于创面,涂厚1~2mm,每隔4至6小时换药一次。
本发明提供的用于烫伤烧伤的组合物及其制备方法与用途的具有以下优点:
本发明提供的用于烫伤烧伤的组合物,能够快速止痛,修复表皮组织、防腐生肌,用后伤口愈合时间快。所得的药膏主要由成品药及凡士林配制而成,配方简单,经济实惠,配制过程容易,设备、原材料来源方便。
该组合物采用的原料选自内服药,外用没有副作用,由其制备而成的药膏具有快速消炎、杀菌,以及清热解毒、止痛、生肌等作用,对创伤有明显效果,可以用于各种烧、烫、灼伤,减少病人痛苦,且不留疤痕。
具体实施方式
以下对本发明的具体实施方式作进一步地说明。
本发明提供的用于烫伤烧伤的组合物,该组合物包含以下成分:马来酸氯苯那敏,糊精、淀粉、磷酸氢钙、羧甲基淀粉钠、硬脂酸镁、醋酸酯、蔗糖、硝酸甘油、凡士林。
优选地,该组合物按重量份数计包含马来酸氯苯那敏0.3~0.6份,糊精0.3~0.6份、淀粉0.3~0.6份、磷酸氢钙0.3~0.6份、羧甲基淀粉钠0.3~0.6份、硬脂酸镁0.3~0.6份、醋酸酯0.3~0.6份、硝酸甘油0.3~0.6份、蔗糖4500~5500份、凡士林8000~12000份。
更优选地,该组合物按重量份数计包含马来酸氯苯那敏0.5份,糊精0.5份、淀粉0.5份、磷酸氢钙0.5份、羧甲基淀粉钠0.5份、硬脂酸镁0.5份、醋酸酯0.5份、硝酸甘油0.5份、蔗糖5000份、凡士林10000份。
最优选地,该组合物按重量计包含马来酸氯苯那敏0.5mg,糊精0.5mg、淀粉0.5mg、磷酸氢钙0.5mg、羧甲基淀粉钠0.5mg、硬脂酸镁0.5mg、醋酸酯0.5mg、硝酸甘油0.5mg、蔗糖5g、凡士林10g。
本发明还提供了该用于烫伤烧伤的组合物的制备方法,该方法为:首先准备材料,然后将固体原料研磨成粉,再按比例与其他原料均匀混合,配制成膏状。
优选地,研磨成粉的粒度范围为50~80目。
本发明也提供了该方法制备的用于烫伤烧伤的组合物的用途,该组合物用于制备针对烧烫伤的的外敷药膏。
该药膏在使用时,先将创面以无菌生理盐水清洁,在清创后将药膏敷于创面,涂厚1~2mm,每隔4至6小时换药一次。
下面结合实施例对本发明提供的用于烫伤烧伤的组合物及其制备方法与用途做更进一步描述。
实施例1~4
各实施例分别按下表1所示的原料成分配比制备组合物。各原料分别符合相应的国家标准。
表1.组合物的配料表(按重量份数计)。
本发明的各实施例还分别提供了该组合物的制备方法,以及制备的组合物的用途。
该方法为:首先准备材料,然后将固体原料研磨成粉,研磨成粉的粒度范围为50~80目,再按比例与其他原料均匀混合,配制成膏状。
该组合物用于制备针对烧烫伤的的外敷药膏。该药膏在使用时,先将创面以无菌生理盐水清洁,在清创后将药膏敷于创面,涂厚1~2mm,每隔4至6小时换药一次。
本发明提供的用于烫伤烧伤的组合物的制备过程为首先准备材料,然后按比例配分,最后进行调和。该组合物采用的原料选自内服药,外用没有副作用,制备而成的药膏经过临床使用,具有快速消炎、杀菌,以及清热解毒、止痛、生肌等作用,对创伤有明显效果,可以用于各种烧、烫、灼伤,用后伤口无痛苦且不易感染,愈合时间快,不会溃烂,不留疤痕。
尽管本发明的内容已经通过上述优选实施例作了详细介绍,但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后,对于本发明的多种修改和替代都将是显而易见的。因此,本发明的保护范围应由所附的权利要求来限定。
Claims (8)
1.一种用于烫伤烧伤的组合物,其特征在于,该组合物包含以下成分:
马来酸氯苯那敏,糊精、淀粉、磷酸氢钙、羧甲基淀粉钠、硬脂酸镁、醋酸酯、蔗糖、硝酸甘油、凡士林。
2.如权利要求1所述的用于烫伤烧伤的组合物,其特征在于,所述的组合物按重量份数计包含马来酸氯苯那敏0.3~0.6份,糊精0.3~0.6份、淀粉0.3~0.6份、磷酸氢钙0.3~0.6份、羧甲基淀粉钠0.3~0.6份、硬脂酸镁0.3~0.6份、醋酸酯0.3~0.6份、硝酸甘油0.3~0.6份、蔗糖4500~5500份、凡士林8000~12000份。
3.如权利要求2所述的用于烫伤烧伤的组合物,其特征在于,所述的组合物按重量份数计包含马来酸氯苯那敏0.5份,糊精0.5份、淀粉0.5份、磷酸氢钙0.5份、羧甲基淀粉钠0.5份、硬脂酸镁0.5份、醋酸酯0.5份、硝酸甘油0.5份、蔗糖5000份、凡士林10000份。
4.如权利要求3所述的用于烫伤烧伤的组合物,其特征在于,所述的组合物按重量计包含马来酸氯苯那敏0.5mg,糊精0.5mg、淀粉0.5mg、磷酸氢钙0.5mg、羧甲基淀粉钠0.5mg、硬脂酸镁0.5mg、醋酸酯0.5mg、硝酸甘油0.5mg、蔗糖5g、凡士林10g。
5.一种如权利要求1~4中任意一项所述的用于烫伤烧伤的组合物的制备方法,其特征在于,所述的方法为:首先准备材料,然后将固体原料研磨成粉,再按比例与其他原料均匀混合,配制成膏状。
6.如权利要求5所述的用于烫伤烧伤的组合物的制备方法,其特征在于,所述的方法中研磨成粉的粒度范围为50~80目。
7.一种如权利要求5所述的方法制备的用于烫伤烧伤的组合物的用途,其特征在于,所述的组合物用于制备针对烧烫伤的的外敷药膏。
8.如权利要求7所述的用于烫伤烧伤的组合物的用途,其特征在于,所述的药膏在使用时,先将创面以无菌生理盐水清洁,在清创后将药膏敷于创面,涂厚1~2mm,每隔4至6小时换药一次。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110490565.2A CN113509491A (zh) | 2021-05-06 | 2021-05-06 | 一种用于烫伤烧伤的组合物及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110490565.2A CN113509491A (zh) | 2021-05-06 | 2021-05-06 | 一种用于烫伤烧伤的组合物及其制备方法与用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113509491A true CN113509491A (zh) | 2021-10-19 |
Family
ID=78064191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110490565.2A Pending CN113509491A (zh) | 2021-05-06 | 2021-05-06 | 一种用于烫伤烧伤的组合物及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113509491A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728167A (zh) * | 2016-12-29 | 2017-05-31 | 崔新民 | 一种烧烫伤外用杀菌止痒药膏 |
-
2021
- 2021-05-06 CN CN202110490565.2A patent/CN113509491A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728167A (zh) * | 2016-12-29 | 2017-05-31 | 崔新民 | 一种烧烫伤外用杀菌止痒药膏 |
Non-Patent Citations (2)
Title |
---|
张志民等: "蔗糖促进烧伤残余创面的愈合" * |
无: "【药品说明书】扑尔敏片", 《百度经验HTTPS://JINGYAN.BAIDU.COM/ARTICLE/E8CDB32B7810AD37052BADC0.HTML》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114099476B (zh) | 一种功能性凝胶层、疤痕贴及其制备方法 | |
CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
CN106728744A (zh) | 一种促进伤口愈合防疤痕的组合物及其制剂 | |
CN1850203A (zh) | 用于治疗烧烫伤的中药制剂和药膏 | |
CN112354005B (zh) | 一种促烧烫伤创面愈合的敷料及其制备方法 | |
CN1060365C (zh) | 一种治疗烧伤、创疡的新药及制备方法 | |
CN113509491A (zh) | 一种用于烫伤烧伤的组合物及其制备方法与用途 | |
CN1259936C (zh) | 治疗烧伤烫伤的中西药组合物 | |
JP2009057290A (ja) | ヒアルロン酸産生促進剤 | |
CN105030958A (zh) | 药物组合物及其应用 | |
CN102283887A (zh) | 一种治疗烧伤的药膏 | |
CN112316108B (zh) | 促进及治疗慢性伤口愈合的组合物和方法 | |
CN112121146B (zh) | 一种用于皮肤创伤的外用凝胶剂及其制备方法 | |
CN1242773C (zh) | 治疗皮肤创伤的药物及其加工方法 | |
CN104435566A (zh) | 一种治疗动物创伤外用药物及制备方法 | |
CN1086955C (zh) | 一种烧烫伤药膏及其制造方法 | |
CN1332673C (zh) | 一种治疗下肢溃疡的中药 | |
CN110624032A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
CN103191163A (zh) | 一种皮肤创面修复药物组合物 | |
CN114931594B (zh) | 一种用于肛门止血止痛的软膏及其制备方法 | |
CN115089562B (zh) | 一种抗菌医用疤痕贴及其制备方法 | |
CN115721674B (zh) | 一种创口护理用组合物及其应用 | |
CN115040580A (zh) | 一种治疗烧烫伤的中药配方及其制备方法 | |
CN117159615A (zh) | 一种聚乙烯醇-聚苹果酸复合植物的烧伤凝胶及其制备方法 | |
CN101032520A (zh) | 一种医治创伤、烫伤的纯中药散剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |